AC, adenylyl cyclase; ANT, anthraniloyl-; CaM, calmodulin; CyaA, Bordetella pertussis adenylyl cyclase toxin; ESI, electrospray ionization; FRET, fluorescence resonance energy transfer; HPLC, high pressure liquid chromatography; k, capacity factor; mAC, mammalian membranous adenylyl cyclase; MANT, methylanthraniloyl-; MS, mass spectroscopy; MW, molecular weight; NDP, nucleoside 5´-diphosphate; NTP, nucleoside 5´-triphosphate; PMEApp, {9-[2-(phosphonomethoxy)ethyl]adenine diphosphate}; EF, full-length edema factor adenylyl cyclase toxin; EF3, catalytic domain of edema factor adenylyl cyclase toxin; R f , retention factor; R t , retention time; TLC, thin layer chromatography.
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Introduction
The spore-forming bacterium Bacillus anthracis exerts its deleterious effects by production of three major exotoxins, i.e. EF, protective antigen, and lethal factor (Jedrzejas, 2002) . EF and lethal factor enter host cells via a complex with membraneassociated protective antigen, which acts as a pH-dependent protein transporter.
Lethal factor, a specific zinc-metalloprotease, inactivates mitogen-activated protein kinase (Hong et al., 2005) . EF possesses ~800 amino acid residues and an apparent molecular weight of ~89 kDa and is a CaM-dependent AC (Drum et al., 2002) . After entering host cells, EF forms a complex with CaM, a mammalian regulatory protein that mediates many aspects of calcium-regulated signaling . The binding of CaM induces a major conformational change in the catalytic domain of EF (Drum et al., 2002) . This rearrangement renders EF highly efficient at catalyzing the conversion of ATP into cAMP, disrupting intracellular signaling pathways through excessive activation of cAMP-dependent signaling pathways (Shen et al., 2005) .
We resolved several crystal structures of nucleotide
•
EF
• CaM complexes and characterized the amino acids that are important for binding of the substrate ATP and catalysis (Drum et al., 2002; Shen et al., 2002 Shen et al., , 2005 . Additionally, we showed that mAC and bacterial AC toxins are potently inhibited by MANT-substituted nucleoside 5'-triphosphates (Gille et al., 2004; Mou et al., 2005 Mou et al., , 2006 Göttle et al., 2007) .
MANT-nucleotides are fluorescent, and we exploited this property to suggest conformational changes associated with activation in purified catalytic subunits of mAC (Mou et al., 2005 (Mou et al., , 2006 and the Bordetella pertussis AC toxin, CyaA (Göttle et al., 2007) . In addition, by combining crystallographic and molecular modeling approaches, we developed a three-site pharmacophore model for mAC and CyaA, with binding domains for the base, the MANT-group and the polyphosphate chain (Gille et al., 2005; Mou et al., 2006; Wang et al., 2007; Göttle et al., 2007) . Those MOL #52340 studies revealed that the catalytic sites of mAC and CyaA exhibit substantial conformational flexibility, accommodating both purine and pyrimidine nucleotides.
Despite this flexibility, the structure/activity relationships of MANT-nucleotides at mAC and CyaA are quite different, offering the opportunity to design potent and isoform-selective AC inhibitors.
In contrast to mAC (Gille et al., 2004 (Gille et al., , 2005 Mou et al., 2005 Mou et al., , 2006 and CyaA (Göttle et al., 2007) , a detailed analysis of MANT-nucleotide/EF interactions has not yet been presented. Therefore, in the present study, we systematically examined the interactions of natural purine and pyrimidine nucleotides and several (M)ANTsubstituted analogues with EF in terms of catalysis, fluorescence changes and molecular modeling.
Materials and Methods
Materials. MANT-GTP, ANT-GTP, MANT-ATP and MANT-ADP were purchased from Jena Bioscience, Germany. PMEApp was supplied by Gilead Sciences, Foster City, CA. GTP, UTP and CTP were purchased from Roche, Mannheim, Germany. ITP, ampicillin, kanamycin, lysozyme enzyme, β -mercaptoethanol, Mes buffer (low moisture content) and dithiothreitol (for molecular biology) were purchased from Sigma-Aldrich, Steinheim, Germany. Tryptone and yeast were purchased from BD Biosciences (Franklin Lakes, NJ). [α−
32 P]ATP (800 MOL #52340 acetonitrile (solvent B) at a constant flow rate of 1.0 ml/min. A gradient profile with the following proportions of solvent B was applied [t (min), % B]: [0, 5] , [10, 5] , [30, 45] .
[ 40, 80] . The chromatograms were monitored at UV absorption at 220 and 254 nm. In addition, a fluorescence detector was used for the analysis of the fluorescent anthraniloylic compounds at λ ex of 350 nm and λ em of 450 nm.
LC/MS online coupling. All samples were filtered using a PTFE filter and injected into a HPLC model 1100 (Agilent Technologies, Waldbronn, Germany). The compound to be analyzed was separated by a C18 column (Phenomenex luna, particle size 3 μm, 150 x 2 mm, Aschaffenburg, Germany). A binary eluent mixture consisting of water (10 mM ammonium acetate) (eluent A) and acetonitrile (eluent B)
was pumped with a constant flow of 0.3 ml/min. The following gradient profile was used (t [min], % B): [0, 5] , [10, 5] , [30, 45] . [40, 80] . The injected volume was 3 μl.
Using a triple stage mass spectrometer (TSQ 7000, Thermoquest Finnigan, Toronto, Canada) the mass of the respective compound was determined.
Preparative HPLC. Compound mixtures were dissolved in water (concentration: 30-50 mg/ml) and filtered using a PTFE filter. Compounds were separated using a HPLC model 1100 (Agilent Technologies, Waldbronn, Germany) fitted with a C18 preparative column (Phenomenex Luna, particle size 10 μ m, 250 x 21.2 mm). Gradient elution was performed with 0.05 M ammonium acetate (solvent A) and acetonitrile (solvent B) at a constant flow rate of 21 ml/min. The chromatograms were monitored by UV absorption at 220 and 254 nm.
MANT-UTP (N-methyl-2'(3')-O-anthraniloyl-uridine-5'-triphospate) or [(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4(3)-hydroxy-2-[[hydroxy-(hydroxy-
This article has not been copyedited and formatted. The final version may differ from this version. Expression and purification of EF and EF3(F586A). The plasmids pProExH6-EF and pProExH6-EF3F586A were prepared as described and amplified in E. coli BL21 (DE3)/pUBS520 cells (Drum et al., 2002; Shen et al., 2002 Shen et al., , 2005 Guo et al., 2004) . The EF3 mutants (H577A, N583A, N583Q, N583H, K353A and K353R)
MANT-UDP (N-methyl-2'(3')-O-anthraniloyl-uridine-5'-diphospate) or [(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4(3)-hydroxy-2-[(hydroxy-
were purified as described (Drum et al., 2002; Shen et al., 2002 Shen et al., , 2005 Guo et al., 2004 ).
Expression and purification of EF was essentially performed as described with minor modifications. Specifically, the imidazole concentration in the elution buffer for the HisTrap fast flow rate Ni column was increased to 200 mM. Moreover, imidazole (20 mM) was added into the sample, thus yielding the same imidazole concentration as in the second wash buffer of the Ni column. The following columns were used for EF protein purification; HisTrap fast flow rate affinity Ni column (5 ml) and resource Q (quaternary ammonium salt) strong anionic exchange column (6 ml) (GE Healthcare, Freiburg/Brsg., Germany). EF3(F586A) mutant was expressed and purified essentially as described with minor modifications. Specifically, the imidazole concentration in the elution buffer for the Ni column was 200 mM, and imidazole (20 mM) was included in the sample. The
HisTrap fast flow rate affinity Ni column (5 ml) was used for immobilized matrix affinity chromatography and the HiPrep 16/10 SP XL column (GE Healthcare) was
This article has not been copyedited and formatted. The final version may differ from this version. , respectively. Tubes were incubated for 10 min at 25°C, and reactions were stopped by the addition of 20 μL of 2.2 N HCl. Denaturated protein was sedimented by a 1-min centrifugation at 13,000 x g. [ Tables 2 and 3 were calculated using the Prism 4.02 software (Graphpad, San Diego, CA).
For determination of the potency of AC toxin inhibitors at various EF3 mutants (H577A, N583A, N583Q, N583H, K353A and K353R), the experiments were essentially performed as described for EF and EF3 with some modifications.
Specifically, the final enzyme concentrations were increased up to 2 nM in order to account for the lower catalytic activity of the mutants. Moreover, the reaction time was prolonged to 20 min at 30°C. For the determination of V max and K m , the ATP/Mn 2+ concentration ranged from 100 μM to 4 mM. The higher substrate concentrations compared to EF were essential in order to obtain saturated enzyme kinetics.
For determination of the potency of AC toxin inhibitors at EF3 in absence of both CaM and Ca
2+
, experiments were performed as described for standard experiments with some modifications in order to increase assay sensitivity.
Specifically, the final enzyme concentration was increased up to 5 nM, and the reaction was stopped after 30 min incubation at 30°C. Moreover, in competition experiments, the concentration of unlabeled ATP was decreased to 20 μM and Mutation of K353 into A353 reduced V max 55-fold and increased K m 10-fold.
EF(K353R) exhibited about 5-fold reduced V max and similar K m compared to the EF3.
There are some differences in the kinetic parameters of EF3 and EF3 mutants in the presence of Mg 2+ (Drum et al., 2002) and Mn 2+ (Table 1) , supporting the view that these divalent cations interact differentially with ACs (Gille et al., 2004; Mou et al., 2005 Mou et al., , 2006 Göttle et al., 2007 , whereas for MANT-GTP, the affinity difference was less than 2-fold. A differential impact of Mg 2+ and Mn 2+ on MANT-nucleotide-affinity was also noted for mAC and CyaA (Gille et al., 2004; Mou et al., 2005 Mou et al., , 2006 Göttle et al., 2007) All natural nucleoside 5'-triphosphates studied inhibited the catalytic activity of that the MANT-group is in a hydrophobic environment (Mou et al., 2005 (Mou et al., , 2006 Göttle et al., 2007) . Previous studies with mAC showed that in the presence of Mn
, FRET signals were much larger than in the presence of Mg 2+ (Mou et al., 2005) . Preliminary
This article has not been copyedited and formatted. The final version may differ from this version. In the absence of CaM, EF3 exhibits a strong emission peak at 350 nm when excited at 280 nm under steady-state conditions ( Figs. 2A and 2C ). Upon addition of the EF activator CaM, an additional prominent fluorescence peak with an emission maximum at 440 nm appeared with MANT-ATP ( Fig. 2A) , reflecting FRET from tryptophan and tyrosine residues to the MANT-group. In EF(F586A), the endogenous tryptophan and tyrosine fluorescence was similar as in EF3, but the FRET signal (difference in fluorescence at an emission wavelength of 440 nm in the presence and absence of calmodulin) was reduced by 55% (Fig. 2B ). With MANT-CTP, only a small FRET signal was apparent with EF3 upon addition of CaM (Fig. 2C) . Even an increase of the final CaM concentration to 3 μM, yielding a 10-fold molar excess of CaM relative to EF3, did not increase FRET with MANT-CTP (data not shown). The small FRET signal with MANT-CTP was reduced by 43% in EF(F586A) (Fig. 2D) .
Analysis of the EF mutants H577A, N583A, N583Q, N583H and K353A with MANT-ATP and MANT-CTP revealed no FRET at all (data not shown). With CaM and MANT-nucleotides alone, i.e. in the absence of EF3, no FRET signal was observed (data not shown).
In FRET experiments, the appearance of the new fluorescence peak at λ em 440 nm would have been expected to be accompanied by a decrease in fluorescence at λ em 350 nm as was the case for mAC (Mou et al., 2005 (Mou et al., , 2006 and CyaA (Göttle et al., 2007) . Rather, a small increase in EF3 fluorescence upon CaM addition was observed (Fig. 2 ). An explanation for these findings could be that the endogenous tyrosine and tryptophan fluorescence of EF3 is quenched by surrounding polar amino acids such as aspartate, glutamate and histidine (Lakowicz, This article has not been copyedited and formatted. The final version may differ from this version. Control experiments with dimethyl sulfoxide ranging from 0-100% (vol/vol) (Hiratsuka, 1983) revealed that MANT-ATP and MANT-CTP possess similar relative increases in fluorescence upon exposure to a hydrophobic environment (λ ex 350 nm;
λ em 400-500 nm) (data not shown). Thus, differences in biophysical properties of nucleotides do not account for the different FRET responses observed with MANT-ATP and MANT-CTP upon interaction with EF. We also studied the interaction of EF with MANT-nucleotides by exciting nucleotides directly at λ em 350 nm. As was true in the FRET experiments (Fig. 2) , the response observed with MANT-ATP at λ em 450 nm was greater than with MANT-CTP (data not shown). align with the positive pole of the amide dipole. However, this difference cannot be the only reason for the higher potency compared to MANT-ATP, because also on the N583A mutant, MANT-CTP is more potent than its ATP analog (Table 3) .
Considering the farther environment of the cytosine oxygen, additional reasons can be suggested. In the minimized model, it is in a 3.3 Å distance from the guanidino group of R329. Moreover, a water molecule can be placed in an ideal position into the EF-MANT-CTP model where it forms three H bonds, bridging the cytosine oxygen with the side chains of R329 and E580. The NH 2 groups of the cytosine and adenine moieties interact similarly with EF-CaM via H bonds to backbone oxygens (3'-MANT-CTP to G578 and/or T579, 3'MANT-ATP to T548 and T579). The signifinace of these interactions is confirmed by the lower potency of MANT-UTP and MANT-GTP (Table   3) . Interestingly, the N583H mutant disproportionately reduces the potency of MANT-ATP, whereas on the N583Q species, MANT-CTP is even less potent than its ATP analog. In the former case, an alignment of the heterocycles should be still possible.
However, the larger glutamine side chain in N583Q restricts the binding cavity for the nucleobases so that the mode of interaction changes. As suggested for MANT-CTP, also the affinity of the other nucleotides to EF3 and EF mutants may be affected by a specific arrangement of water molecules.
The MANT nucleotides used in the assays are mixtures of 2'-MANT and 3'-MANT isomers, and there is spontaneous isomerization between the two species under physiological conditions (Hiratsuka, 1983 (Hiratsuka, , 2003 Jameson and Eccleston, 1997) . So far, only the putative binding mode of 3'-MANT-isomers has been considered. The question arises whether the MANT group may fit to the same EFCaM site in both isomers as shown for the binding of MANT-nucleotides to CyaA (Göttle et al., 2007) . endo conformation of the ribosyl moiety, present also in the complex of 3'-deoxy-ATP with EF-CaM (Drum et al., 2002) . This geometry implies an axial position of the 2'-MANT group which may then project to the space between H351 and F586.
Additionally, an intramolecular H bond between the 3'-hydroxy group and the proximal α-phosphate oxygen is possible. Fig. 4E, showing 
Discussion
The major goal of the present study was to characterize the interaction of the catalytic site of EF with (M)ANT-nucleotides possessing various purine and pyrimidine bases in order to better understand the molecular mechanisms of EF inhibition and to provide the basis for the rational development of potent and selective EF inhibitors. Such EF inhibitors could be useful compounds to treat EF toxinemia and antibiotic-resistant Bacillus anthracis strains (Jedrzejas, 2002) .
In previous studies, we developed a three-site pharmacophore model for mAC and CyaA toxin with binding regions for the base, the MANT-group and the polyphosphate chain (Gille et al., 2005; Mou et al., 2006; Wang et al., 2007; Göttle et al., 2007) . Those studies revealed that the MANT-group and the polyphosphate chain are the major determinants of inhibitor potency, whereas the base plays a relatively small role in this respect. This is reflected by the fact that the catalytic sites of mAC This article has not been copyedited and formatted. The final version may differ from this version. and CyaA are conformationally flexible and accommodate both purine and pyrimidine nucleotides.
Likewise, in EF, the (M)ANT-group and the length of the polyphosphate chain have a substantial impact on inhibitor potency, and EF accommodates various purine and pyrimidine bases (Table 3 ). These data indicate that the three-site binding model developed for mAC and CyaA can also be extended to EF. The structure/activity relationships of (MANT)-nucleotides at EF, CyaA and mAC are different, indicating that in principle, the development of potent and AC isoform-specific inhibitors is feasible. Most strikingly, CTP inhibited EF more than 400-fold more potently than mAC (Table 3 ) (Gille et al., 2005) . Substitution of the 2'(3')-O-ribosyl position of CTP with a MANT group decreased the K i value from 5 μM to 100 nM, yielding an EF inhibitor that is even 5-10-fold more potent than MANT-ATP in the presence of Mn 2+ (Tables 2 and 3 ).
The highly unexpected preference of EF for the base cytosine prompted us to analyze EF inhibition by MANT-CTP and MANT-ATP in more detail. The analysis of enzyme inhibition kinetics revealed that both MANT-CTP and MANT-ATP are competitive EF inhibitors, i.e. they bind to the same site as, and freely compete with, the substrate ATP (Fig. 1) . These data rule out the existence of a hitherto unidentified cytosine base-preferring nucleotide-binding site in the structurally very complex EF protein ( Fig. 4A ) (Drum et al., 2002; Shen et al., 2002) . Kinetic FRET competition experiments with the non-fluorescent ATP analog PMEApp revealed that both MANT-ATP and MANT-CTP reversibly bind to the catalytic site (Fig. 3) In order dissect possible differences in the binding modes of MANT-ATP and MANT-CTP to EF, we studied their interaction with several EF mutants in terms of enzyme inhibition and fluorescence spectroscopy. A previous study had shown that F586 mediates π-stacking interactions with 2'-deoxy-3'-ANT-ATP, resulting in a fluorescence increase upon excitation of the ANT-group . In agreement with those data, mutation of F586 reduced the potency of MANT-ATP and largely reduced the CaM-dependent FRET of MANT-ATP (Table 2 and Fig. 2 ). F586
is also important for the interaction with MANT-CTP as is revealed by the 6-fold reduction in potency. However, compared to MANT-ATP, the FRET signal with MANT-CTP in EF was much smaller, and the F586A mutation had a smaller inhibitory effect on the FRET. This difference in FRET cannot be explained by a lower CaM-affinity of EF bound to MANT-CTP compared to the protein complex bound to MANT-ATP since a 10-fold molar excess of CaM relative to EF did not yield a larger FRET with MANT-CTP. The models shown in Fig. 4 suggest a similar binding mode of MANT-CTP and its ATP analog. However, subtle differences due to the nucleobases occur and may account for the higher potency and the small FRET signal of MANT-CTP. In particular, the cytosine moiety may form water-mediated hydrogen bonds with R329 and E580 and favorably fit to the amide dipole of N583.
Additionally, the flexibility of the bound cytosine should be greater than in the case of the bulkier adenine ring. Together with the specific charge distribution in the vicinity of the nucleobase, this may lead to absorption and thus attenuation of the FRET energy which is mainly due to tyrosine and tryptophan residues in switch C.
H577 plays a crucial role in catalysis as is reflected by the very low catalytic activity of the H577A mutant (Table 1) (Drum et al., 2002; Guo et al., 2004) .
Nonetheless, the catalytic activity of the H577A mutant was sufficiently large to This article has not been copyedited and formatted. The final version may differ from this version. determine substrate-and MANT-nucleotide affinity. Indeed, this mutation does not exert detrimental effect on substrate-and inhibitor binding per se (Tables 1 and 2 ).
N583 forms a crucial hydrogen bond with the ribosyl moiety of nucleotides bound to the catalytic site of EF (Drum et al., 2002) . Accordingly, replacement of N583 by a non-hydrogen bond-forming amino acid (N583A) or hydrogen bondforming amino acid with a different spatial arrangement of the bonding partners (N583Q and N383H) substantially decreases catalytic activity of the resulting EF mutants and also increases K m (Table 1 ) (Drum et al., 2002) . Thus, it was also not surprising that N583 mutants substantially reduced the potencies of MANT-ATP and MANT-CTP (Table 2 ). However, whereas the N583A mutation and the N583H mutation affected inhibitor potencies to a similar extent, the potency of MANT-CTP was much more strongly reduced by the N583Q mutation than the potency of MANT-ATP. These findings suggest that the binding of MANT-CTP is severely impaired by the longer side chain of Q as compared to N, indicative for a substantial spatial constraint in this part of the binding pocket.
The carboxyl group of E588 and the amino group of K353 form an ionic bond that locks the base into the catalytic site (Drum et al., 2002) . Disruption of this ionic bond by the K353A mutation largely reduces catalytic activity and lowers substrate affinity (Drum et al., 2002) (Table 1 ). The K353R mutation that alters the spatial arrangement of the catalytic site but still allows ionic bridge formation displays less severe impairment of catalysis and no change in K m (Table 1) . Intriguingly, binding of MANT-CTP to the catalytic site is much more sensitive to disruption of ionic bond formation between E588 and K353 and reorientation of the ionic bond than binding of MANT-ATP (Table 2) , further corroborating the notion that there are subtle differences in the binding modes of MANT-ATP and MANT-CTP.
This article has not been copyedited and formatted. The final version may differ from this version. forming a salt bridge with R329). To explain the unaltered potency of the MANT inhibitors at EF alone, we postulate that the nucleotides stabilize switch B in a conformation like that in EF-CaM. The substrate may act similarly in terms of affinity, but the resulting switch B conformation is insufficient for high catalytic activity.
Experiments with membrane-permeable CaM inhibitors (Wolberg and Zimmerman, 1984) will have to answer the question whther the CaM-independent catalytic activity of EF is of pathophysiological relevance.
In conclusion, through a combination of enzymological, fluorescence spectroscopy, mutagenesis and molecular modeling approaches, we have shown μM CaCl 2 , 100 mM KCl and 5 mM MnCl 2 , pH 7.4. Nucleotides were added to the buffer to yield 300 nM final concentrations. EF3/EF3(F586A) (300 nM final concentration) was added followed by the addition of CaM (1 μM final concentration).
Emission was scanned at an excitation wavelength of 280 nm after each addition.
The buffer and the MANT-nucleotide basal fluorescence was subtracted from the fluorescence after addition of EF3/EF3(F586A) (dotted purple line) and CaM (solid blue line). Shown are superimposed recordings of a representative experiment.
Similar data were obtained in 5 independent experiments. a.u., arbitrary unit.
This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. , the ATP/Mn 2+ concentration was 20 μM and the enzyme concentration was 5 nM. Nucleotides were added at different concentrations as appropriate to obtain saturated concentration-response curves. Inhibition curves were analyzed by non-linear regression using the Prism 4.02 software.
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Inhibitory potencies of various purine and pyrimidine nucleotides at EF were determined as described under "Materials and Methods". K i values are given in μM and are the means ± SD of 3-4 independent experiments performed in triplicates. The K m value of EF for ATP in the presence of Mg 2+ was 120 ± 6.5 μM. Reaction mixtures contained 5 mM MnCl 2 or 5 mM MgCl 2 , 100 mM KCl, 100 μM CaCl 2 , 40 μM ATP, [α− 32 P]ATP (0.2-0.4 μCi/tube), 100 μM cAMP and 100 nM CaM. Nucleotides were added at different concentrations as appropriate to construct saturated concentration-response curves. Inhibition curves were analyzed by non-linear regression using the Prism 4.02 software.
